

Centum Electronics Limited

January 16, 2025

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long-term bank facilities	267.13 (Enhanced from 232.13)	CARE BBB; Stable	Reaffirmed
Long-term / Short-term bank facilities	166.00	CARE BBB; Stable / CARE A3+	Reaffirmed

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

Ratings assigned to enhanced bank facilities of Centum Electronics Limited (CEL) continue to derive strength from the vintage business of close to three decades and its established association with a reputed clientele base from which CEL has been receiving repeat orders. Ratings also derive strength from the above-average financial risk profile marked by satisfactory capital structure and debt coverage indicators at standalone level. The company's revenues have increased and profit before interest, lease rentals, depreciation, and taxation (PBILDT) margins have shown improvement in FY24. Ratings also take note of CEL's growing order book size, especially in the high-margin built-to-suit segment, which augurs well for its growth in the near-to-medium term. Ratings also take note of the company's plans to raise funds by way of preferential allotment, private placement or qualified institutions placement (QIP) upto ₹250 crore for expansion of existing business and to manage increasing working requirements aligned with expected increase in scale of operations. These rating strengths are partially offset by the working capital intensive operations and its exposure to the French subsidiary, Centum T&S (CTS), which has been incurring losses though the management is of the view that CTS will break even in Q4FY25. CEL has extended financial support to CTS in FY24 and H1FY 25. However, even after loading CTS' debt repayments on CEL standalone, DSCR is expected to remain satisfactory.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Increase in the scale of operations while maintaining PBILDT margin over 15%.
- Total debt to gross cash accrual (TD/GCA) less than 3x.

Negative factors

- Unforeseen financial support to CTS adversely impacting CEL's debt protection metrics.
- Significant decline in the scale of operations and overall gearing over 1.5x.

Analytical approach: Standalone

Outlook: Stable

Stable outlook reflects CARE Ratings Limited's (CARE Ratings') expectation that the business would continue to scale up with improvement in profitability aided by growing order book position.

Detailed description of key rating drivers:

Key strengths

Diversified product and revenue mix across different geographies and industries

The company's offerings range from customised product design and development, manufacturing services, and turnkey solutions for mission-critical applications in the defence, aerospace, space, industrial, medical and communications industries. The company broadly operates under two business segments including Strategic Electronic Business Unit (SEBU) and the Electronics Manufacturing Solutions Business Unit (EMS). CTS (a subsidiary of CEL) has an engineering division in France, with electronic system designing capabilities in the industrial sector. CTS' acquisition by CEL was primarily to take advantage of CTS' designing capabilities in the industrial sector, as CEL's designing is largely limited to the defence and aerospace industries. Although the synergy is yet to take place, under a steady state, CEL will become a one-stop solution to the companies across sectors for their

¹Complete definition of ratings assigned are available at www.careedge.in and other CARE Ratings Limited's publications.

electronic manufacturing and design needs. In CARE Ratings' opinion, CEL's presence in multiple divisions would help mitigating the exposure to inherent cyclicity involved with this industry.

Experienced promoters and established track record of the company

Apparao V Mallavarapu Rao, chairman and managing director (CMD), has over three decades of experience in managing the electronics business. CEL is engaged in designing and manufacturing high-end electronics modules, systems and subsystems, since 1994. He has ventured and successfully managed joint ventures (JVs) with several multinational companies. The CMD is supported by Nikhil Mallavarapu, executive director, and Tanya Mallavarapu, non-executive director. The company has a high level of corporate governance with six independent directors having vast experience in the field of electronics system designing and manufacturing. CARE Ratings believes such long established track record would help the company in maintaining strong order book.

Established association with a reputed clientele base

CEL has delivered mission-critical electronics on almost all satellite programs of ISRO including the ambitious Chandrayaan and Mangalyaan projects and also delivered 300 to 500 components for almost every Indian space mission. The clientele base consists of reputed defence segment companies such as Space Application Centre, ISRO, DRDO's, ABB, Thales, and RAFAEL among others.

Above-average financial profile, marked by satisfactory coverage indicators

On standalone basis, CEL's turnover has grown by 26% in FY24. The PBILDT margins improved to 12.65% in FY24 (FY23: 10.72%) and is expected to be in the range of 12%-13%, considering increasing order book with large ticket orders in BTS segment which is a high margin business. The company continues to maintain strong order book of ₹1303 crore as on September 30, 2024, which provides revenue visibility for medium term. CARE Ratings expects that with a sizeable order book in hand, the company is likely to maintain growth and profitability in the near-to-medium term.

Key weaknesses

Working capital intensive operations

The company's business operations are working capital intensive considering long gestation period from winning to execution of order. Amid container and semiconductor shortage, lead time and procurement cost increased. The procurement orders are placed based on the client's acceptance to absorb the price difference and pay advances to reduce the lead time. CEL has been able to collect advances for executing orders and reliance on the WC limits is low. Average utilisation is at 69%.

Investment in loss making subsidiary

CEL took over Adetel in 2016, which was a stressed asset, and is currently named CTS. At the time of acquisition, Adetel had two divisions – an energy division and an engineering division. The energy division was incurring losses, as finding a market was challenging, and it was sold off in FY20. Although CTS' operations were envisaged to be profitable, fixed price contract margins and high employee costs among others impacted the turnaround. CEL has infused ₹33 crore in CTS in FY24, of which ₹14 crore was towards existing put option liability and ₹19 crore as support to subsidiary and further invested ₹1 million in H1FY25. The management expects that no further support would be required as CTS is likely to breakeven by Q4FY25. In FY24, revenues have improved to ₹458.01 crore (PY: ₹447 crore).

Liquidity: Adequate

The company's liquidity is adequate with expected improvement in cash accruals aided by strong demand in the company's business and expansion plans. The company's average WC utilisation stands at 69%. However, in case of continuing losses in subsidiary requiring funding support from CEL which affects its liquidity would be a key rating monitorable.

Applicable criteria

[Definition of Default](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Rating Watch](#)

[Manufacturing Companies](#)

[Financial Ratios – Non financial Sector](#)

[Short Term Instruments](#)

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Industrials	Capital goods	Industrial manufacturing	Industrial products

CEL was founded in 1994 in Bengaluru by Apparao V Mallavarapu, a first-generation entrepreneur. The company is in designing and manufacturing electronic systems and manufactures high-end electronic modules, subsystems and systems used in the aerospace, defence, and industrial electronics sectors.

Brief Financials (₹ crore)	March 31, 2023 (A)	March 31, 2024 (A)	September 30, 2024 (UA)
Total operating income	500.55	632.80	299.61
PBILDT	53.68	80.06	33.38
PAT	19.40	36.25	14.10
Overall gearing (times)	0.39	0.33	NA
Interest coverage (times)	3.58	4.75	4.42

A: Audited UA: Unaudited; Note: these are latest available financial results

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance	Coupon Rate (%)	Maturity Date	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Fund-based - LT-Term Loan	-	-	-	March 2029	35.43	CARE BBB; Stable
Fund-based - LT/ST-CC/PC/Bill Discounting	-	-	-	-	166.00	CARE BBB; Stable / CARE A3+
Non-fund-based - LT-Bank Guarantee	-	-	-	-	231.70	CARE BBB; Stable

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT/ST-CC/PC/Bill Discounting	LT/ST	166.00	CARE BBB; Stable /	1)CARE BBB;	1)CARE BBB;	1)CARE BBB;	1)CARE BBB;

				CARE A3+	Stable / CARE A3+ (03-Jan-25)	Stable / CARE A3+ (19-Dec-23)	Stable / CARE A3+ (08-Nov-22) 2)CARE BBB; Stable / CARE A3+ (01-Apr-22)	Stable / CARE A3+ (18-May-21)
2	Non-fund-based - LT-Bank Guarantee	LT	231.70	CARE BBB; Stable	1)CARE BBB; Stable (03-Jan-25)	1)CARE BBB; Stable (19-Dec-23)	1)CARE BBB; Stable (08-Nov-22) 2)CARE BBB; Stable (01-Apr-22)	1)CARE BBB; Stable (18-May-21)
3	Fund-based - LT-Term Loan	LT	35.43	CARE BBB; Stable	1)CARE BBB; Stable (03-Jan-25)	1)CARE BBB; Stable (19-Dec-23)	-	-

LT: Long term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	Fund-based - LT/ ST-CC/PC/Bill Discounting	Simple
3	Non-fund-based - LT-Bank Guarantee	Simple

Annexure-5: Lender details

To view lender-wise details of bank facilities please [click here](#)

Note on complexity levels of rated instruments: CARE Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact us

Media Contact Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in Relationship Contact Saikat Roy Senior Director CARE Ratings Limited Phone: +91-22-67543404	Analytical Contacts Karthik Raj K Director CARE Ratings Limited Phone: +91-80-46625555 E-mail: karthik.raj@careedge.in Himanshu Jain Associate Director CARE Ratings Limited Phone: +91-080-46625528 E-mail: himanshu.jain@careedge.in
--	---

E-mail: saiikat.roy@careedge.inGautami Shanker
Lead Analyst
CARE Ratings Limited
E-mail: Gautami.Shanker@careedge.in**About us:**

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For detailed Rationale Report and subscription information,
please visit www.careedge.in**